Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directors

Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of  Medimetriks Pharmaceuticals, which develops, licenses, and commercializes prescription skincare products with a focus on dermatology and select specialty markets.

Mr. Lary, who will serve on Medimetriks' Audit Committee, brings 20 years of financial and investment experience to the Company. Mr. Lary is currently Managing Director, Investments, at Domain Capital Advisors, LLC. He is responsible for investment sourcing, acquisition due diligence, asset management and client development, managing asset types including late-stage venture capital and private equity. Prior to joining Domain, Mr. Lary was co-founder and principal of a strategic management and financial consulting firm. Mr. Lary's career began at PricewaterhouseCoopers, where he served as a Senior Manager in the Real Estate Business Advisory Services group and was responsible for a variety of strategic consulting projects.  Mr. Lary is a Certified Public Accountant and earned his BSM in Accounting from Tulane University. 

Mr. Resnick, who will serve on the Compensation Committee, brings over 20 years of healthcare industry experience to Medimetriks, with specific expertise in Pharmacy Benefit Management. Mr. Resnick is a co-founder of Solid Benefit Guidance, a healthcare consulting firm with a focus on the financial, clinical, and service components of pharmacy and employee benefit management. Prior to founding Solid Benefit Guidance, Mr. Resnick held senior positions at several local and national health plans, including serving as General Manager at Medco Health Solutions, Vice President of National Account Sales and Account Management at Empire Blue Cross Blue Shield and Senior Benefit Consultant at CODA/KVI. Mr. Resnick earned a Bachelor of Science degree at the State University of New York at Brockport, and later received his MBA in HealthCare Administration from the Baruch/Mt. Sinai School of Medicine.

Medimetriks' Chairman and CEO, Bradley Glassman, stated, "Medimetriks Pharmaceuticals is excited to welcome Mr. Resnick and Mr. Lary, both highly experienced and successful experts in their areas of specialty, as independent members of our Board of Directors.  Mr. Lary's financial expertise, coupled with Mr. Resnick's extensive background in Pharmacy Benefit Management, will bring a meaningful contribution to Medimetriks.  The Management Team, together with the Board of Directors, looks forward to their contributions to Medimetriks' corporate strategic planning."